Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non–Small Cell Lung Cancer

(2019) Lucian Beer et al.   CLINICAL NUCLEAR MEDICINE

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

(2019) Robert Haddad et al.   CANCER

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

(2019) Caroline Robert et al.   LANCET ONCOLOGY

Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade

(2019) Amy L. Shergold et al.   PHARMACOLOGICAL RESEARCH

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

(2019) Suzanne L. Topalian et al.   JAMA Oncology

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

(2018) M T Tetzlaff et al.   ANNALS OF ONCOLOGY

Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents

(2018) Matteo Santoni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Mechanisms of Resistance to PD-1 and PD-L1 Blockade

(2018) Theodore S. Nowicki et al.   CANCER JOURNAL

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

(2018) Julia A Beaver et al.   LANCET ONCOLOGY

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

(2018) Michael R. Migden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer

(2018) Daniel P. Petrylak et al.   JAMA Oncology

Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

(2018) Jun Tang et al.   NATURE REVIEWS DRUG DISCOVERY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

(2016) F. Cardoso et al.   ANNALS OF ONCOLOGY

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

A Threshold Level of Intratumor CD8 + T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1

(2015) Shin Foong Ngiow et al.   CANCER RESEARCH

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

(2009) David Jackman et al.   JOURNAL OF CLINICAL ONCOLOGY